Compare
DBV Technologies S.A. vs Zeo ScientifiX, Inc. vs Fate Therapeutics Inc vs Prime Medicine, Inc.
| Latest fiscal year | DBV Technologies S.A. DBVT | Zeo ScientifiX, Inc. ZEOX | Fate Therapeutics Inc FATE | Prime Medicine, Inc. PRME |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-10-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.64M | $5.20M | $6.65M | $4.63M |
| Revenue growth (YoY) | +35.8% | +12.5% | -51.2% | +55.3% |
| Gross margin | n/a | 82.1% | n/a | n/a |
| Operating margin | n/m | -103.6% | n/m | n/m |
| Net margin | n/m | -106.2% | n/m | n/m |
| Net income | -$146.95M | -$5.52M | -$136.31M | -$201.14M |
| EPS (Diluted) | -$1.05 | -$0.86 | -$1.15 | -$1.35 |
| Operating cash flow | -$121.18M | -$718.0K | -$106.08M | -$162.56M |
| Free cash flow | -$121.71M | -$741.0K | -$112.04M | -$167.09M |
| Cash & equivalents | $194.17M | n/a | $46.63M | $63.03M |
| Total assets | $233.72M | $1.53M | $318.94M | $342.73M |
| Total liabilities | $64.95M | $2.95M | n/a | $221.87M |
| Shareholders' equity | $168.77M | -$1.42M | $207.18M | $120.87M |
| Return on year-end equity | -87.1% | n/a | -65.8% | -166.4% |
| Shares outstanding | n/a | 6.75M | 115.36M | 180.51M |
Revenue, most recent five fiscal years
| Fiscal year | DBV Technologies S.A. | Zeo ScientifiX, Inc. | Fate Therapeutics Inc | Prime Medicine, Inc. |
|---|---|---|---|---|
| Latest | $5.64M Ended 2025-12-31 | $5.20M Ended 2025-10-31 | $6.65M Ended 2025-12-31 | $4.63M Ended 2025-12-31 |
| 1 year earlier | $4.15M Ended 2024-12-31 | $4.62M Ended 2024-10-31 | $13.63M Ended 2024-12-31 | $2.98M Ended 2024-12-31 |
| 2 years earlier | $15.73M Ended 2023-12-31 | $4.56M Ended 2023-10-31 | $63.53M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $4.84M Ended 2022-12-31 | $6.49M Ended 2022-10-31 | $96.30M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $5.71M Ended 2021-12-31 | $5.60M Ended 2021-10-31 | $55.85M Ended 2021-12-31 | $0 Ended 2021-12-31 |